Innovative Vaccination: A New Era in Cancer Prevention
Keywords:
Vaccination, Cancer , Malignancies, PreventionAbstract
Cancer remains one of the leading causes of death worldwide, prompting researchers to explore novel prevention and treatment strategies. One of the most promising advancements in oncology is the development of innovative cancer vaccines. Unlike traditional vaccines that primarily prevent infectious diseases, cancer vaccines are designed to stimulate the immune system to recognize and eliminate cancerous cells. These vaccines hold great potential in both cancer prevention and treatment, ushering in a new era of precision medicine. Preventive cancer vaccines aim to protect against viruses known to cause malignancies. The most notable examples include the human papillomavirus (HPV) vaccine, which prevents cervical and other HPV-related cancers, and the hepatitis B vaccine, which reduces the risk of liver cancer by preventing hepatitis B virus infection. These vaccines have significantly reduced cancer incidence in vaccinated populations, highlighting the effectiveness of immunization as a preventive measure. On the other hand, therapeutic cancer vaccines work by boosting the immune system’s ability to detect and destroy tumor cells. Advances in vaccine technology, such as peptide-based, dendritic cell, and mRNA vaccines, are being explored for various cancers, including melanoma, lung, and breast cancer. With ongoing research and clinical trials, cancer vaccination is poised to revolutionize cancer prevention and treatment. As immunotherapy continues to evolve, innovative vaccination strategies offer hope for reducing cancer burden and improving patient outcomes worldwide.
References
Ahmed KK, Geary SM, Salem AK. Applying biodegradable particles to enhance cancer vaccine efficacy. Immunol Res. 2014;59(1-3):220-8.
Al-Hawary SIS, Jasim SA, Hjazi A, Oghenemaro EF, Kaur I, Kumar A, et al. Nucleic acid-based vaccine for ovarian cancer cells; bench to bedside. Cell Biochem Funct. 2024;42(2):e3978.
Alqarni A, Jasim SA, Altalbawy FMA, Kaur H, Kaur I, Rodriguez-Benites C, et al. Challenges and opportunities for cancer stem cell-targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell-dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes. J Biochem Mol Toxicol. 2024;38(6):e23719.
Altinoz MA, Ozpinar A, Ozpinar A, Hacker E, Elmaci İ. Could hepatitis B vaccine act as an adjuvant to lower risk and relapses of cancer? Clin Exp Pharmacol Physiol. 2019;46(8):694-704.
Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother. 2014;10(11):3354-68.
Ammi R, De Waele J, Willemen Y, Van Brussel I, Schrijvers DM, Lion E, et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther. 2015;146:120-31.
Arab A, Yazdian-Robati R, Behravan J. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development. Arch Immunol Ther Exp (Warsz). 2020;68(1):2.
Arriola E, Ottensmeier C. TG4010: a vaccine with a therapeutic role in cancer. Immunotherapy. 2016;8(5):511-9.
Ashraf MU, Jeong Y, Roh SE, Bae YS. Transendothelial migration (TEM) of in vitro generated dendritic cell vaccine in cancer immunotherapy. Arch Pharm Res. 2019;42(7):582-90.
Banday AH, Jeelani S, Hruby VJ. Cancer vaccine adjuvants--recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol. 2015;37(1):1-11.
Barrière J, Carles M, Audigier-Valette C, Re D, Adjtoutah Z, Seitz-Polski B, et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. Eur J Cancer. 2022;162:182-93.
Baxevanis CN, Fortis SP, Ardavanis A, Perez SA. Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design. Cancers (Basel). 2020;12(10).
Beckwith DM, Cudic M. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design. Semin Immunol. 2020;47:101389.
Behzadi E, Halabian R, Hosseini HM, Fooladi AAI. Bacterial toxin's DNA vaccine serves as a strategy for the treatment of cancer, infectious and autoimmune diseases. Microb Pathog. 2016;100:184-94.
Berzofsky JA, Terabe M, Trepel JB, Pastan I, Stroncek DF, Morris JC, et al. Cancer vaccine strategies: translation from mice to human clinical trials. Cancer Immunol Immunother. 2018;67(12):1863-9.
Bin Umair M, Akusa FN, Kashif H, Seerat EF, Butt F, Azhar M, et al. Viruses as tools in gene therapy, vaccine development, and cancer treatment. Arch Virol. 2022;167(6):1387-404.
Bolhassani A, Javanzad S, Saleh T, Hashemi M, Aghasadeghi MR, Sadat SM. Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum Vaccin Immunother. 2014;10(2):321-32.
Bolivar AM, Duzagac F, Sinha KM, Vilar E. Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome. Mol Aspects Med. 2023;93:101204.
Bouzid R, Peppelenbosch M, Buschow SI. Opportunities for Conventional and in Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. Cancers (Basel). 2020;12(5).
Bowen CM, Sinha KM, Vilar E. Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes. Clin Colon Rectal Surg. 2024;37(3):146-56.
Bowen WS, Svrivastava AK, Batra L, Barsoumian H, Shirwan H. Current challenges for cancer vaccine adjuvant development. Expert Rev Vaccines. 2018;17(3):207-15.
Brauns T, Leblanc P, Gelfand JA, Poznanski M. Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine? Expert Rev Vaccines. 2015;14(3):435-46.
Brezar V, Godot V, Cheng L, Su L, Lévy Y, Seddiki N. T-Regulatory Cells and Vaccination "Pay Attention and Do Not Neglect Them": Lessons from HIV and Cancer Vaccine Trials. Vaccines (Basel). 2016;4(3).
Bright RK. Preclinical support for tumor protein D52 as a cancer vaccine antigen. Hum Vaccin Immunother. 2023;19(3):2273699.
Brugiapaglia S, Spagnolo F, Intonti S, Novelli F, Curcio C. Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality? Cells. 2024;13(18).
Bryan JT, Buckland B, Hammond J, Jansen KU. Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. Curr Opin Chem Biol. 2016;32:34-47.
Buonaguro L, Tagliamonte M. Selecting Target Antigens for Cancer Vaccine Development. Vaccines (Basel). 2020;8(4).
Buonaguro L, Tagliamonte M. Peptide-based vaccine for cancer therapies. Front Immunol. 2023;14:1210044.
Burke EE, Kodumudi K, Ramamoorthi G, Czerniecki BJ. Vaccine Therapies for Breast Cancer. Surg Oncol Clin N Am. 2019;28(3):353-67.
Butow P, Shaw J, Bartley N, Milch V, Sathiaraj R, Turnbull S, et al. Vaccine hesitancy in cancer patients: A rapid review. Patient Educ Couns. 2023;111:107680.
Butterfield LH. Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother. 2016;65(7):805-12.
Cachay ER, Mathews WC. Use of human papillomavirus vaccine in HIV-infected men for the prevention of anal dysplasia and cancer. AIDS Rev. 2014;16(2):90-100.
Cai J, Wang H, Wang D, Li Y. Improving Cancer Vaccine Efficiency by Nanomedicine. Adv Biosyst. 2019;3(3):e1800287.
Cai X, Xu L. Human Papillomavirus-Related Cancer Vaccine Strategies. Vaccines (Basel). 2024;12(11).
Casper C, Corey L, Cohen JI, Damania B, Gershon AA, Kaslow DC, et al. KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine. NPJ Vaccines. 2022;7(1):108.
Catanzaro E, Feron O, Skirtach AG, Krysko DV. Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy. Front Immunol. 2022;13:925290.
Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape. Front Immunol. 2021;12:679344.
Chamani R, Ranji P, Hadji M, Nahvijou A, Esmati E, Alizadeh AM. Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis. Eur J Pharmacol. 2018;831:87-93.
Chandarana C, Tiwari A. A Review of Clinical Trials of Cancer and Its Treatment as a Vaccine. Rev Recent Clin Trials. 2024;19(1):7-33.
Chen C, Xu Y, Meng H, Bao H, Hu Y, Li C, et al. Nano-Oncologic Vaccine for Boosting Cancer Immunotherapy: The Horizons in Cancer Treatment. Nanomaterials (Basel). 2025;15(2).
Chen M, Zhou Y, Fu Y, Wang Q, Wu C, Pan X, et al. Biomaterials-assisted cancer vaccine delivery: preclinical landscape, challenges, and opportunities. Expert Opin Drug Deliv. 2024;21(7):1143-54.
Chen R, Fulton KM, Twine SM, Li J. IDENTIFICATION OF MHC PEPTIDES USING MASS SPECTROMETRY FOR NEOANTIGEN DISCOVERY AND CANCER VACCINE DEVELOPMENT. Mass Spectrom Rev. 2021;40(2):110-25.
Cheng EM, Tsarovsky NW, Sondel PM, Rakhmilevich AL. Interleukin-12 as an in situ cancer vaccine component: a review. Cancer Immunol Immunother. 2022;71(9):2057-65.
Cheng L, Wang R, Yan J. A review of urinary HPV testing for cervical cancer management and HPV vaccine surveillance: rationale, strategies, and limitations. Eur J Clin Microbiol Infect Dis. 2024;43(12):2247-58.
Cherryholmes GA, Stanton SE, Disis ML. Current methods of epitope identification for cancer vaccine design. Vaccine. 2015;33(51):7408-14.
Chesson CB, Zloza A. Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer. Nanomedicine (Lond). 2017;12(23):2693-706.
Circelli L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L. Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines (Basel). 2015;3(3):544-55.
Clifton GT, Gall V, Peoples GE, Mittendorf EA. Clinical Development of the E75 Vaccine in Breast Cancer. Breast Care (Basel). 2016;11(2):116-21.
Clifton GT, Kohrt HE, Peoples GE. Critical issues in cancer vaccine trial design. Vaccine. 2015;33(51):7386-92.
Connors JM, Iba T. Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer. Thromb Res. 2022;213 Suppl 1:S77-s83.
Crombet Ramos T, Rodríguez PC, Neninger Vinageras E, Garcia Verdecia B, Lage Davila A. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines. 2015;14(10):1303-11.
Dailey GP, Crosby EJ, Hartman ZC. Cancer vaccine strategies using self-replicating RNA viral platforms. Cancer Gene Ther. 2023;30(6):794-802.
Danaeifar M, Negahdari B, Eslam HM, Zare H, Ghanaat M, Koushali SS, et al. Polymeric nanoparticles for DNA vaccine-based cancer immunotherapy: a review. Biotechnol Lett. 2023;45(9):1053-72.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18(5):313-9.
Devaraja K, Singh M, Sharan K, Aggarwal S. Coley's Toxin to First Approved Therapeutic Vaccine-A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment. Biomedicines. 2024;12(12).
Dhanushkumar T, M ES, Selvam PK, Rambabu M, Dasegowda KR, Vasudevan K, et al. Advancements and hurdles in the development of a vaccine for triple-negative breast cancer: A comprehensive review of multi-omics and immunomics strategies. Life Sci. 2024;337:122360.
Di Bonito P, Accardi L, Galati L, Ferrantelli F, Federico M. Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes. Cancers (Basel). 2019;11(2).
Diana G, Corica C. Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence? Oral Oncol. 2021;115:105168.
Ding H, Zhang J, Zhang F, Xu Y, Yu Y, Liang W, et al. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer. Front Oncol. 2022;12:990877.
Duan LJ, Wang Q, Zhang C, Yang DX, Zhang XY. Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy. Front Immunol. 2022;13:923647.
Ede NJ, Good AJ, Tobias J, Garner-Spitzer E, Zielinski CC, Wiedermann U. Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers. Front Oncol. 2022;12:939356.
Fan C, Qu H, Wang X, Sobhani N, Wang L, Liu S, et al. Cancer/testis antigens: from serology to mRNA cancer vaccine. Semin Cancer Biol. 2021;76:218-31.
Fantini M, Tsang KY, Arlen PM. Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells. Expert Rev Vaccines. 2024;23(1):812-29.
Feng C, Li Y, Ferdows BE, Patel DN, Ouyang J, Tang Z, et al. Emerging vaccine nanotechnology: From defense against infection to sniping cancer. Acta Pharm Sin B. 2022;12(5):2206-23.
Feng C, Tan P, Nie G, Zhu M. Biomimetic and bioinspired nano-platforms for cancer vaccine development. Exploration (Beijing). 2023;3(3):20210263.
Ford ME, Cannady K, Nahhas GJ, Knight KD, Chavis C, Crawford B, et al. Assessing an intervention to increase knowledge related to cervical cancer and the HPV vaccine. Adv Cancer Res. 2020;146:115-37.
Freeman-Keller M, Goldman J, Gray J. Vaccine immunotherapy in lung cancer: Clinical experience and future directions. Pharmacol Ther. 2015;153:1-9.
Gabai VL, Shifrin VI. Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy. Int Rev Immunol. 2014;33(5):375-82.
Gajdosik Z. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today (Barc). 2014;50(4):301-7.
Galati D, Zanotta S, Bocchino M, De Filippi R, Pinto A. The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies? Cancer Immunol Immunother. 2021;70(7):1797-809.
Gao T, Cen Q, Lei H. A review on development of MUC1-based cancer vaccine. Biomed Pharmacother. 2020;132:110888.
García-Pardo M, Gorria T, Malenica I, Corgnac S, Teixidó C, Mezquita L. Vaccine Therapy in Non-Small Cell Lung Cancer. Vaccines (Basel). 2022;10(5).
Garland SM, Brown DR. Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer. Expert Opin Biol Ther. 2014;14(4):527-34.
Giudice GC, Sonpavde GP. Vaccine approaches to treat urothelial cancer. Hum Vaccin Immunother. 2024;20(1):2379086.
Glybochko PV, Fisenko VP. IMMUNOTHERAPY OF BLADDER CANCER. BCG VACCINE: PRINCIPLES OF ACTION, EFFICACY AND SAFETY. Eksp Klin Farmakol. 2016;79(10):34-43.
González FE, Gleisner A, Falcón-Beas F, Osorio F, López MN, Salazar-Onfray F. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother. 2014;10(11):3261-9.
Grant M, Ni Lee L, Chinnakannan S, Tong O, Kwok J, Cianci N, et al. Unlocking cancer vaccine potential: What are the key factors? Hum Vaccin Immunother. 2024;20(1):2331486.
Gu Q, Qi A, Wang N, Zhou Z, Zhou X. Unlocking Immunity: Innovative prostate cancer vaccine strategies. Int Immunopharmacol. 2024;142(Pt A):113137.
Gugulothu KN, Anvesh Sai P, Suraparaju S, Karuturi SP, Pendli G, Kamma RB, et al. WT1 Cancer Vaccine in Advanced Pancreatic Cancer: A Systematic Review. Cureus. 2024;16(3):e56934.
Guo M, Dou J. Advances and perspectives of colorectal cancer stem cell vaccine. Biomed Pharmacother. 2015;76:107-20.
Gupta DS, Gupta DS, Abjani NK, Dave Y, Apte K, Kaur G, et al. Vaccine-based therapeutic interventions in lung cancer management: A recent perspective. Med Oncol. 2024;41(11):249.
Gupta R, Rady PL, Doan HQ, Tyring SK. Development of a β-HPV vaccine: Updates on an emerging frontier of skin cancer prevention. J Clin Virol. 2020;126:104348.
Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. Int Immunopharmacol. 2021;90:107247.
Han S, Lee SY, Wang WW, Tan YB, Sim RHZ, Cheong R, et al. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers (Basel). 2020;12(11).
He Y, Ding Y, Cao B, Huang Y, Wang X. COVID-19 vaccine development from the perspective of cancer patients. Hum Vaccin Immunother. 2021;17(10):3281-7.
Hein KZ, Yao S, Fu S. Wilms' Tumor 1 (WT1): The Vaccine for Cancer. J Immunother Precis Oncol. 2020;3(4):165-71.
Hernández AM, Vázquez AM. Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines. 2015;14(1):9-20.
Hong J, Xu XW, Yang J, Zheng J, Dai SM, Zhou J, et al. Knowledge about, attitude and acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China: A cross-sectional survey. J Integr Med. 2022;20(1):34-44.
Hossain F, Kandalai S, Zhou X, Zhang N, Zheng Q. Chemical and Synthetic Biology Approaches for Cancer Vaccine Development. Molecules. 2022;27(20).
Huang QT, Zhong M, Gao YF, Huang LP, Huang Q, Wang W, et al. Can HPV vaccine have other health benefits more than cancer prevention? A systematic review of association between cervical HPV infection and preterm birth. J Clin Virol. 2014;61(3):321-8.
Huang X, Zhang G, Tang TY, Gao X, Liang TB. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil Med Res. 2022;9(1):53.
Hundal J, Miller CA, Griffith M, Griffith OL, Walker J, Kiwala S, et al. Cancer Immunogenomics: Computational Neoantigen Identification and Vaccine Design. Cold Spring Harb Symp Quant Biol. 2016;81:105-11.
Ibeanu GC, Rowaiye AB, Okoli JC, Eze DU. Microbiome Differences in Colorectal Cancer Patients and Healthy Individuals: Implications for Vaccine Antigen Discovery. Immunotargets Ther. 2024;13:749-74.
Ibrahim M, Kim P, Marawar R, Avgerinos KI. Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis. J Prev Alzheimers Dis. 2024;11(5):1355-62.
Ikewaki N, Dedeepiya VD, Raghavan K, Rao KS, Vaddi S, Osawa H, et al. β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review). Oncol Rep. 2022;47(1).
Jahan S, Mukherjee S, Ali S, Bhardwaj U, Choudhary RK, Balakrishnan S, et al. Pioneer Role of Extracellular Vesicles as Modulators of Cancer Initiation in Progression, Drug Therapy, and Vaccine Prospects. Cells. 2022;11(3).
Jeon D, Hill E, McNeel DG. Toll-like receptor agonists as cancer vaccine adjuvants. Hum Vaccin Immunother. 2024;20(1):2297453.
John-Akinola YO, Ndikom CM, Oluwasanu MM, Adebisi T, Odukoya O. Cervical Cancer and Human Papillomavirus Vaccine Knowledge, Utilisation, Prevention Educational Interventions and Policy Response in Nigeria: A Scoping Review. Cancer Control. 2022;29:10732748221130180.
Jucht A, Dumont S, Pooley C, Gonzalez Castro LN. Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas. Ther Adv Vaccines Immunother. 2023;11:25151355231206163.
Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, et al. Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review. Cells. 2023;12(17).
Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines (Basel). 2021;9(12).
Kardani K, Bolhassani A, Namvar A. An overview of in silico vaccine design against different pathogens and cancer. Expert Rev Vaccines. 2020;19(8):699-726.
Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, et al. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol. 2023;212:115545.
Kaumaya PT. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncol. 2020;16(23):1767-91.
Kaur A, Baldwin J, Brar D, Salunke DB, Petrovsky N. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. Curr Opin Chem Biol. 2022;70:102172.
Kazi B, Talukdar Z, Schriefer J. Quality Improvement Interventions to Enhance Vaccine Uptake in Cancer Patients: A Systematic Review. J Healthc Qual. 2024;46(2):81-94.
Kelly M, McNeel D, Fisch P, Malkovsky M. Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. Immunol Lett. 2018;193:1-10.
Kelly-Hanku A, Newland J, Aggleton P, Ase S, Aeno H, Fiya V, et al. HPV vaccination in Papua New Guinea to prevent cervical cancer in women: Gender, sexual morality, outsiders and the de-feminization of the HPV vaccine. Papillomavirus Res. 2019;8:100171.
Kenoosh HA, Pallathadka H, Hjazi A, Al-Dhalimy AMB, Zearah SA, Ghildiyal P, et al. Recent advances in mRNA-based vaccine for cancer therapy; bench to bedside. Cell Biochem Funct. 2024;42(2):e3954.
Kessler AL, Bruno MJ, Buschow SI. The Potential of Soluble Human Leukocyte Antigen Molecules for Early Cancer Detection and Therapeutic Vaccine Design. Vaccines (Basel). 2020;8(4).
Khatami M. Deceptology in cancer and vaccine sciences: Seeds of immune destruction-mini electric shocks in mitochondria: Neuroplasticity-electrobiology of response profiles and increased induced diseases in four generations - A hypothesis. Clin Transl Med. 2020;10(8):e215.
Kim H, Griffith TS, Panyam J. Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine. J Pharmacol Exp Ther. 2019;370(3):715-24.
Kirner A, Mayer-Mokler A, Reinhardt C. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother. 2014;10(11):3179-89.
Kissick HT. Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens as Vaccine Targets for Cancer. Cold Spring Harb Perspect Biol. 2018;10(11).
Koido S, Okamoto M, Kobayashi M, Shimodaira S, Sugiyama H. Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer. Discov Med. 2017;24(130):41-9.
Kondapuram SK, Ramachandran HK, Arya H, Coumar MS. Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development. Life Sci. 2023;335:122260.
Koti M, Morales A, Graham CH, Siemens DR. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy. J Immunother Cancer. 2020;8(2).
Kumar A, Dixit S, Srinivasan K, M D, Vincent P. Personalized cancer vaccine design using AI-powered technologies. Front Immunol. 2024;15:1357217.
Kumar S, Malviya R, Uniyal P. Vaccine for Targeted Therapy of Lung Cancer: Advances and Developments. Curr Drug Targets. 2024;25(8):526-9.
Lancaster EM, Jablons D, Kratz JR. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development. Genet Test Mol Biomarkers. 2020;24(2):59-66.
Lane DL, Neelapu SS, Xu G, Weaver O. COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT. Korean J Radiol. 2021;22(12):1938-45.
Lebossé F, Zoulim F. [Hepatitis B vaccine and liver cancer]. Bull Cancer. 2021;108(1):90-101.
Lei L, Huang D, Gao H, He B, Cao J, Peppas NA. Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy. Sci Adv. 2022;8(47):eadc8738.
Li R, Chibbar R, Xiang J. Novel EXO-T vaccine using polyclonal CD4(+) T cells armed with HER2-specific exosomes for HER2-positive breast cancer. Onco Targets Ther. 2018;11:7089-93.
Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu J, et al. mRNA vaccine in cancer therapy: Current advance and future outlook. Clin Transl Med. 2023;13(8):e1384.
Liang J, Zhao X. Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development. Cancer Biol Med. 2021;18(2):352-71.
Lim J, Lee SA, Khil EK, Byeon SJ, Kang HJ, Choi JA. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature. Semin Oncol. 2021;48(4-6):283-91.
Lim YT. Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease. Clin Exp Vaccine Res. 2015;4(1):54-8.
Liu N, Xiao X, Zhang Z, Mao C, Wan M, Shen J. Advances in Cancer Vaccine Research. ACS Biomater Sci Eng. 2023;9(11):5999-6023.
Liu W, Tang H, Li L, Wang X, Yu Z, Li J. Peptide-based therapeutic cancer vaccine: Current trends in clinical application. Cell Prolif. 2021;54(5):e13025.
Luchner M, Reinke S, Milicic A. TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases. Pharmaceutics. 2021;13(2).
Lundstrom K. Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer. Vaccines (Basel). 2021;9(10).
Luo W, Yang G, Luo W, Cao Z, Liu Y, Qiu J, et al. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. Cancer Cell Int. 2020;20:66.
Lybaert L, Vermaelen K, De Geest BG, Nuhn L. Immunoengineering through cancer vaccines - A personalized and multi-step vaccine approach towards precise cancer immunity. J Control Release. 2018;289:125-45.
Malla R, Srilatha M, Muppala V, Farran B, Chauhan VS, Nagaraju GP. Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials. J Control Release. 2024;370:707-20.
Manoutcharian K, Gevorkian G. Are we getting closer to a successful neoantigen cancer vaccine? Mol Aspects Med. 2024;96:101254.
Marriott M, Post B, Chablani L. A comparison of cancer vaccine adjuvants in clinical trials. Cancer Treat Res Commun. 2023;34:100667.
Martin-Lluesma S, Graciotti M, Grimm AJ, Boudousquié C, Chiang CL, Kandalaft LE. Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer? Curr Opin Biotechnol. 2020;65:190-6.
Matsui H, Hazama S, Shindo Y, Nagano H. Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies. Expert Rev Anticancer Ther. 2018;18(12):1205-17.
Mazzio E, Barnes A, Badisa R, Council S, Soliman KFA. Plants against cancer: the immune-boosting herbal microbiome: not of the plant, but in the plant. Basic concepts, introduction, and future resource for vaccine adjuvant discovery. Front Oncol. 2023;13:1180084.
McCarthy PM, Clifton GT, Vreeland TJ, Adams AM, O'Shea AE, Peoples GE. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence. Expert Opin Investig Drugs. 2021;30(1):5-11.
McCarthy PM, Valdera FA, Smolinsky TR, Adams AM, O'Shea AE, Thomas KK, et al. Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. Front Immunol. 2023;14:1090533.
Meena SS, Kosgei BK, Soko GF, Tingjun C, Chambuso R, Mwaiselage J, et al. Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control. NPJ Vaccines. 2025;10(1):18.
Mensah FA, Mehta MR, Lewis JS, Jr., Lockhart AC. The Human Papillomavirus Vaccine: Current Perspective and Future Role in Prevention and Treatment of Anal Intraepithelial Neoplasia and Anal Cancer. Oncologist. 2016;21(4):453-60.
Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41.
Miltz A, Price H, Shahmanesh M, Copas A, Gilson R. Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure. PLoS One. 2014;9(3):e90348.
Mody N, Dubey S, Sharma R, Agrawal U, Vyas SP. Dendritic cell-based vaccine research against cancer. Expert Rev Clin Immunol. 2015;11(2):213-32.
Mohsin SF. Vaccine a promising immunotherapy option for head and neck cancer patients. Pak J Med Sci. 2024;40(7):1578-83.
Morales CG, Jimenez NR, Herbst-Kralovetz MM, Lee NR. Novel Vaccine Strategies and Factors to Consider in Addressing Health Disparities of HPV Infection and Cervical Cancer Development among Native American Women. Med Sci (Basel). 2022;10(3).
Morera-Díaz Y, Gavilondo JV, Bequet-Romero M, Sánchez Ramírez J, Hernández-Bernal F, Selman-Housein KH, et al. Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside. Semin Oncol. 2018;45(1-2):68-74.
Morse MA, Gwin WR, 3rd, Mitchell DA. Vaccine Therapies for Cancer: Then and Now. Target Oncol. 2021;16(2):121-52.
Mougel A, Terme M, Tanchot C. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade. Front Immunol. 2019;10:467.
Nahas MR, Rosenblatt J, Lazarus HM, Avigan D. Anti-cancer vaccine therapy for hematologic malignancies: An evolving era. Blood Rev. 2018;32(4):312-25.
Nakahara Y, Kouro T, Igarashi Y, Kawahara M, Sasada T. Prospects for a personalized peptide vaccine against lung cancer. Expert Rev Vaccines. 2019;18(7):703-9.
Näsman A, Du J, Dalianis T. A global epidemic increase of an HPV-induced tonsil and tongue base cancer - potential benefit from a pan-gender use of HPV vaccine. J Intern Med. 2020;287(2):134-52.
Neek M, Kim TI, Wang SW. Protein-based nanoparticles in cancer vaccine development. Nanomedicine. 2019;15(1):164-74.
Nikfarjam S, Rezaie J, Kashanchi F, Jafari R. Dexosomes as a cell-free vaccine for cancer immunotherapy. J Exp Clin Cancer Res. 2020;39(1):258.
Nordin ML, Azemi AK, Nordin AH, Nabgan W, Ng PY, Yusoff K, et al. Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects. Pharmaceuticals (Basel). 2023;16(7).
O'Neill AM, Dwyer R. Primary prevention of cervical cancer in women: Human papillomavirus vaccine. Eur J Obstet Gynecol Reprod Biol. 2023;281:29-31.
Obara W, Kanehira M, Katagiri T, Kato R, Kato Y, Takata R. Present status and future perspective of peptide-based vaccine therapy for urological cancer. Cancer Sci. 2018;109(3):550-9.
Ogasawara M. Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives. Hum Vaccin Immunother. 2024;20(1):2296735.
Okamoto M, Kobayashi M, Yonemitsu Y, Koido S, Homma S. Dendritic cell-based vaccine for pancreatic cancer in Japan. World J Gastrointest Pharmacol Ther. 2016;7(1):133-8.
Olatunji G, Kokori E, Yusuf IA, Akinmoju O, Isarinade T, Komolafe R, et al. AE37 HER2-targeted vaccine in the prevention of breast cancer recurrence: A mini narrative review of current evidence. Medicine (Baltimore). 2023;102(52):e36793.
Oliveres H, Caglevic C, Passiglia F, Taverna S, Smits E, Rolfo C. Vaccine and immune cell therapy in non-small cell lung cancer. J Thorac Dis. 2018;10(Suppl 13):S1602-s14.
Pampeno C, Opp S, Hurtado A, Meruelo D. Sindbis Virus Vaccine Platform: A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment. Int J Mol Sci. 2024;25(5).
Pan D, Liu J, Huang X, Wang S, Kuerban K, Yan Y, et al. Challenges and New Directions in Therapeutic Cancer Vaccine Development. Vaccines (Basel). 2024;12(12).
Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, et al. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. J Immunol Res. 2018;2018:4325874.
Pappas G, Saloustros E, Boutis A, Tsoukalas N, Nikolaou M, Christopoulou A, et al. Vaccine third dose and cancer patients: necessity or luxury? ESMO Open. 2021;6(6):100306.
Pathak P, Pajai S, Kesharwani H. A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer. Cureus. 2022;14(9):e28710.
Pender A, Jones RL, Pollack S. Optimising Cancer Vaccine Design in Sarcoma. Cancers (Basel). 2018;11(1).
Petrie K, Wells A, Eckert LO. Human Papillomavirus Vaccine: The Cancer Prevention Moonshot. Obstet Gynecol Clin North Am. 2023;50(2):339-48.
Petrizzo A, Tagliamonte M, Tornesello M, Buonaguro FM, Buonaguro L. Systems vaccinology for cancer vaccine development. Expert Rev Vaccines. 2014;13(6):711-9.
Prabani KIP, Weerasekara I, Damayanthi H. COVID-19 vaccine acceptance and hesitancy among patients with cancer: a systematic review and meta-analysis. Public Health. 2022;212:66-75.
Prawiningrum AF, Paramita RI, Panigoro SS. Immunoinformatics Approach for Epitope-Based Vaccine Design: Key Steps for Breast Cancer Vaccine. Diagnostics (Basel). 2022;12(12).
Qiao Y, Agboola OS, Hu X, Wu Y, Lei L. Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine. Stem Cell Rev Rep. 2020;16(6):1049-61.
Quinn M, Erkes DA, Snyder CM. Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector. Immunotherapy. 2016;8(2):211-21.
Quintella CM, Quintella HM, Rohweder M, Quintella GM. Advances in patent applications related to cancer vaccine using CpG-ODN and OX40 association. Expert Opin Ther Pat. 2020;30(4):287-301.
Rahman M, Sahoo A, Almalki WH, Salman Almujri S, Aodah A, Alnofei AA, et al. Three-dimensional cell culture: Future scope in cancer vaccine development. Drug Discov Today. 2024;29(9):104114.
Rausch S, Schwentner C, Stenzl A, Bedke J. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum Vaccin Immunother. 2014;10(11):3146-52.
Ren S, Zhang Z, Li M, Wang D, Guo R, Fang X, et al. Cancer testis antigen subfamilies: Attractive targets for therapeutic vaccine (Review). Int J Oncol. 2023;62(6).
Renduchintala K, Arevalo M, Fonseca G, Haver MK, Gwede CK, Pabbathi S, et al. Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review. Vaccine. 2024;42(22):125995.
Rezaei T, Davoudian E, Khalili S, Amini M, Hejazi M, de la Guardia M, et al. Strategies in DNA vaccine for melanoma cancer. Pigment Cell Melanoma Res. 2021;34(5):869-91.
Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, et al. The Human Vaccines Project: A roadmap for cancer vaccine development. Sci Transl Med. 2016;8(334):334ps9.
Ruzzi F, Riccardo F, Conti L, Tarone L, Semprini MS, Bolli E, et al. Cancer vaccines: Target antigens, vaccine platforms and preclinical models. Mol Aspects Med. 2025;101:101324.
Saadeldin MK, Abdel-Aziz AK, Abdellatif A. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Med Hypotheses. 2021;146:110365.
Saavedra D, Crombet T. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Front Immunol. 2017;8:269.
Sadeghi MS, Sangrizeh FH, Jahani N, Abedin MS, Chaleshgari S, Ardakan AK, et al. Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development. Environ Res. 2023;237(Pt 2):117027.
Sadeghi Najafabadi SA, Bolhassani A, Aghasadeghi MR. Tumor cell-based vaccine: an effective strategy for eradication of cancer cells. Immunotherapy. 2022;14(8):639-54.
Saeed Y, Zhong R, Sun Z. Advances in traditional herbal formulation based nano-vaccine for cancer immunotherapy: Unraveling the enigma of complex tumor environment and multidrug resistance. Int Immunopharmacol. 2024;132:111948.
Sasada T, Yamada A, Noguchi M, Itoh K. Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem. 2014;21(21):2332-45.
Sayour EJ, Mendez-Gomez HR, Mitchell DA. Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes. Int J Mol Sci. 2018;19(10).
Schneble E, Clifton GT, Hale DF, Peoples GE. Peptide-Based Cancer Vaccine Strategies and Clinical Results. Methods Mol Biol. 2016;1403:797-817.
Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, et al. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31.
Seya T, Shime H, Takeda Y, Tatematsu M, Takashima K, Matsumoto M. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci. 2015;106(12):1659-68.
Shahvali S, Rahiman N, Jaafari MR, Arabi L. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Drug Deliv Transl Res. 2023;13(7):2041-56.
Shanmugaraj B, Priya LB, Mahalakshmi B, Subbiah S, Hu RM, Velmurugan BK, et al. Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy. Life Sci. 2020;250:117550.
Shaw I, Boafo GF, Ali YS, Liu Y, Mlambo R, Tan S, et al. Advancements and prospects of lipid-based nanoparticles: dual frontiers in cancer treatment and vaccine development. J Microencapsul. 2024;41(3):226-54.
Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019;78:8-16.
Shindo Y, Hazama S, Nagano H. [Cancer Vaccine Focused on Neoantigens]. Gan To Kagaku Ryoho. 2019;46(9):1367-71.
Shiro R, Tsunoda I. [HPV vaccinations and cervical cancer in Japan: Flaws in alleged experimental evidence for molecular mimicry and animal models of HPV vaccine-induced "adverse reactions "]. Uirusu. 2024;74(1):17-28.
Shirota H, Tross D, Klinman DM. CpG Oligonucleotides as Cancer Vaccine Adjuvants. Vaccines (Basel). 2015;3(2):390-407.
Signorelli C, Odone A, Ciorba V, Cella P, Audisio RA, Lombardi A, et al. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiol Infect. 2017;145(10):1962-82.
Singh A, Koutsoumpli G, van de Wall S, Daemen T. An alphavirus-based therapeutic cancer vaccine: from design to clinical trial. Cancer Immunol Immunother. 2019;68(5):849-59.
Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J, et al. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert Rev Vaccines. 2016;15(3):367-87.
Subbarayan R, Srinivasan D, Balakrishnan R, Kumar A, Usmani SS, Srivastava N. DNA damage response and neoantigens: A favorable target for triple-negative breast cancer immunotherapy and vaccine development. Int Rev Cell Mol Biol. 2024;389:104-52.
Sun H, Bu F, Li L, Zhang X, Yan J, Huang T. COVID-19 vaccine response and safety in patients with cancer: An overview of systematic reviews. Front Public Health. 2022;10:1072137.
Sunoqrot S, Abdel Gaber SA, Abujaber R, Al-Majawleh M, Talhouni S. Lipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery. ACS Appl Bio Mater. 2024;7(8):4998-5019.
Sutherland SIM, Ju X, Horvath LG, Clark GJ. Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer. Front Immunol. 2021;12:641307.
Tadros J, Rahnama-Moghadam S. Erythema annulare centrifugum-type eruption in a patient undergoing cancer vaccine immunotherapy. Dermatol Online J. 2018;24(10).
Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, et al. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. Expert Opin Biol Ther. 2018;18(7):829-35.
Tagliamonte M, Cavalluzzo B, Mauriello A, Ragone C, Buonaguro FM, Tornesello ML, et al. Molecular mimicry and cancer vaccine development. Mol Cancer. 2023;22(1):75.
Tan T, Deng ST, Wu BH, Yang Q, Wu MW, Wu H, et al. mRNA Vaccine - A New Cancer Treatment Strategy. Curr Cancer Drug Targets. 2023;23(9):669-81.
Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol. 2016;28(7):329-38.
Thakur A, Parra DC, Motallebnejad P, Brocchi M, Chen HJ. Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics. Bioact Mater. 2022;10:281-94.
Tojjari A, Saeed A, Singh M, Cavalcante L, Sahin IH, Saeed A. A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma. Vaccines (Basel). 2023;11(8).
Torigoe T, Hirohashi Y, Tsukahara T, Kanaseki T, Kochin V, Sato N. [The path to innovative drug development of cancer vaccine: from discovery of tumor antigens to clinical trials]. Nihon Rinsho Meneki Gakkai Kaishi. 2014;37(2):90-5.
Tousian B, Khosravi AR, Ghasemi MH, Kadkhodaie M. Biomimetic functionalized metal organic frameworks as multifunctional agents: Paving the way for cancer vaccine advances. Mater Today Bio. 2024;27:101134.
Tran S, Truong TH, Narendran A. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis. Eur J Cancer. 2021;159:259-74.
Tran T, Blanc C, Granier C, Saldmann A, Tanchot C, Tartour E. Therapeutic cancer vaccine: building the future from lessons of the past. Semin Immunopathol. 2019;41(1):69-85.
Trigo S, Gonzalez K, Di Matteo L, Ismail A, Elmansy H, Shahrour W, et al. Bacillus Calmette-Guerin vaccine and bladder cancer incidence: Scoping literature review and preliminary analysis. Arch Ital Urol Androl. 2021;93(1):1-8.
Tsai HJ. Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine. Taiwan J Obstet Gynecol. 2015;54(2):112-5.
Tsentemeidou A, Fyrmpas G, Stavrakas M, Vlachtsis K, Sotiriou E, Poutoglidis A, et al. Human Papillomavirus Vaccine to End Oropharyngeal Cancer. A Systematic Review and Meta-Analysis. Sex Transm Dis. 2021;48(9):700-7.
van der Sluis TC, van der Burg SH, Arens R, Melief CJ. New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer. Curr Opin Immunol. 2015;35:9-14.
Vermaelen K. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses. Front Immunol. 2019;10:8.
Vielot NA, Brewer NT. Optimizing Cancer Prevention in Adolescents by Improving HPV Vaccine Delivery. N C Med J. 2023;85(1):33-6.
Wang L, Pegram MD, Wu JC. Induced pluripotent stem cells as a novel cancer vaccine. Expert Opin Biol Ther. 2019;19(11):1191-7.
Wang M, Cao JX, Liu YS, Xu BL, Li D, Zhang XY, et al. Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis. BMJ Open. 2015;5(4):e006321.
Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020;471:88-102.
Wang Y, Liu C, Pang J, Li Z, Zhang J, Dong L. The Extra-Tumoral Vaccine Effects of Apoptotic Bodies in the Advancement of Cancer Treatment. Small. 2025:e2410503.
Wei L, Huang K, Han H, Liu RY. Human Papillomavirus Infection in Penile Cancer: Multidimensional Mechanisms and Vaccine Strategies. Int J Mol Sci. 2023;24(23).
Wei L, Xie X, Liu J, Qiao Y, Zhao F, Wu T, et al. Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China. Indian J Gynecol Oncol. 2021;19(3):51.
Wei WZ, Jones RF, Juhasz C, Gibson H, Veenstra J. Evolution of animal models in cancer vaccine development. Vaccine. 2015;33(51):7401-7.
Wei X, Chen F, Xin K, Wang Q, Yu L, Liu B, et al. Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects. Transl Oncol. 2019;12(5):733-8.
Wen R, Umeano AC, Kou Y, Xu J, Farooqi AA. Nanoparticle systems for cancer vaccine. Nanomedicine (Lond). 2019;14(5):627-48.
Wilski NA, Snyder CM. From Vaccine Vector to Oncomodulation: Understanding the Complex Interplay between CMV and Cancer. Vaccines (Basel). 2019;7(3).
Wooster AL, Girgis LH, Brazeale H, Anderson TS, Wood LM, Lowe DB. Dendritic cell vaccine therapy for colorectal cancer. Pharmacol Res. 2021;164:105374.
Wu M, Wang S, Chen JY, Zhou LJ, Guo ZW, Li YH. Therapeutic cancer vaccine therapy for acute myeloid leukemia. Immunotherapy. 2021;13(10):863-77.
Xia W, Wang J, Xu Y, Jiang F, Xu L. L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review. J Thorac Dis. 2014;6(10):1513-20.
Yang B, Jeang J, Yang A, Wu TC, Hung CF. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10(11):3153-64.
Yang W, Zhang D, Li Z, Zhang K. Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022;172:41-50.
Ye T, Li F, Ma G, Wei W. Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors. Adv Drug Deliv Rev. 2021;177:113927.
Ye Z, Qian Q, Jin H, Qian Q. Cancer vaccine: learning lessons from immune checkpoint inhibitors. J Cancer. 2018;9(2):263-8.
Yi Y, Yu M, Li W, Zhu D, Mei L, Ou M. Vaccine-like nanomedicine for cancer immunotherapy. J Control Release. 2023;355:760-78.
Zdrehus R, Delcea C, Mocan L. Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development. Pharmaceutics. 2024;16(3).
Zefferino R, Conese M. A Vaccine against Cancer: Can There Be a Possible Strategy to Face the Challenge? Possible Targets and Paradoxical Effects. Vaccines (Basel). 2023;11(11).
Zemp F, Rajwani J, Mahoney DJ. Rhabdoviruses as vaccine platforms for infectious disease and cancer. Biotechnol Genet Eng Rev. 2018;34(1):122-38.
Zhang R, Billingsley MM, Mitchell MJ. Biomaterials for vaccine-based cancer immunotherapy. J Control Release. 2018;292:256-76.
Zhang X, Yang B, Ni Q, Chen X. Materials engineering strategies for cancer vaccine adjuvant development. Chem Soc Rev. 2023;52(9):2886-910.
Zhao J, Liao B, Gong L, Yang H, Li S, Li Y. Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis. Hum Vaccin Immunother. 2023;19(2):2254262.
Zhao X, Zhao R, Nie G. Nanocarriers based on bacterial membrane materials for cancer vaccine delivery. Nat Protoc. 2022;17(10):2240-74.
Zhou W, Lu X, Tian F, Luo Q, Zhou W, Yang S, et al. Vaccine Therapies for Prostate Cancer: Current Status and Future Outlook. Vaccines (Basel). 2024;12(12).
Amiri H, Ghaneiyan M, Farjami P, Mehran H, Mohammadzadeh S, Ghaderi S, et al. AI-Enhanced Virtual Clinics and Telemedicine for Cancer Treatment. Kindle. 2024;4(1):1-207.
Farrokhi M, Khouzani SJ, Farrokhi M, Jalayeri H, Faranoush P, Babaei M, et al. Artificial Intelligence and Deep Learning for Screening and Risk Assessment of Cancers. Kindle. 2024;4(1):1-140.
Farrokhi M, Taheri F, Adibnia E, Mehrtabar S, Rassaf Z, Tooyserkani SH, et al. The AI Diagnostician: Improving Medical Diagnosis with Artificial Intelligence. Kindle. 2024;4(1):1-219.
Farrokhi M, Taheri F, Bayat Z, Damiri M, Farrokhi M, Ghadirzadeh E, et al. Role of Lifestyle Medicine in the Prevention and Treatment of Diseases. Kindle. 2024;4(1):1-219.
Farrokhi M, Taheri F, Farrokhi M, Emtiazi N, Talebi M, Akbari A, et al. Human and AI: Collaborative Medicine in the Age of Technology. Kindle. 2024;4(1):1-160.
Farrokhi M, Taheri F, Farrokhi M, Heydari Z, Darbani R, Salbi M, et al. Advancements and Innovations in Cancer Management: A Comprehensive Perspective. Kindle. 2024;4(1):1-161.
Farrokhi M, Taheri F, Farrokhi M, Moeini A, Tooyserkani SH, Shahali A, et al. Anti-Aging Strategies to Prevent Diseases: Promoting Longevity and Optimal Health. Kindle. 2024;4(1):1-194.
Farrokhi M, Taheri F, Farrokhi M, Tosi YEK, Ghadirzadeh E, Bagheri M, et al. Nanomedicine: Technologies and Applications. Kindle. 2024;4(1):1-196.
Farrokhi M, Taheri F, Moeini A, Farrokhi M, Alireza MZS, Farahmandsadr M, et al. Artificial Intelligence for Remote Patient Monitoring: Advancements, Applications, and Challenges. Kindle. 2024;4(1):1-261.
Farrokhi M, Taheri F, Moeini A, Farrokhi M, Khouzani PJ, Ghadirzadeh E, et al. Artificial Intelligence for Drug Development, Personalized Prescriptions, and Adverse Event Prediction. Kindle. 2024;4(1):1-180.
Karimian S, Taheri F, Farrokhi M, Farrokhi M, Bayat Z, Zadeh SAM, et al. Digital Health and Wearable Technologies. Kindle. 2024;4(1):1-240.
Khorsand M-S, Heidari S, Darbani R, Tosi YEK, Pourasad MH, Rajabloo Y, et al. AI Chatbots and Telemedicine in Cancer Care: Supporting Patients and Enhancing Communications. Kindle. 2024;4(1):1-205.
Nemati P, Khalaji A, Rajabloo Y, Kazemi MH, Nouri S, Mohebbi S, et al. AI and Deep Learning in Understanding the Etiology and Pathogenesis of Cancers. Kindle. 2024;4(1):1-173.
Rahmani E, Farrokhi M, Nemati P, Riahi S, Rostami ME, Golafzani RS, et al. Global Health Challenges. Kindle. 2024;4(1):1-218.
Rigi A, Harati K, Abbaspour M, Fattahpour SF, Hosseini P, Fard AM, et al. AI and Deep Learning in Understanding the Etiology and Pathogenesis of Autoimmune Diseases. Kindle. 2024;4(1):1-182.
Taheri F, Farrokhi M, Rajabloo Y, Razavi N, Shirdel E, Hooshiar MH, et al. Complementary and alternative medicine (CAM). Kindle. 2024;4(1):1-193.
Zahmatkesh N, Babaei SS, Manesh SH, Abbaspour M, Ghadirzadeh E, Salimian N, et al. Artificial Intelligence for Prediction of Metastasis Risk and Survival. Kindle. 2024;4(1):1-205.
Rahmani E, Farrokhi M, Aghajan A, Gholampour G, Ghoodjani E, Shemshadigolafzani R, et al. AI-Driven Strategies for Improving Patient Quality of Life. Kindle. 2025;5(1):1-214.
Rezaei M, Azarshab M. Research Hotspots and Global Mapping of Publications in the Role of Artificial Intelligence in Cancer: A Bibliometric Study. Journal of Reviews in Medical Sciences. 2024;4(1):1-10.
